CN103936652A - Anti-HCV drug Boceprevir intermediate IV, preparation method and application thereof - Google Patents

Anti-HCV drug Boceprevir intermediate IV, preparation method and application thereof Download PDF

Info

Publication number
CN103936652A
CN103936652A CN201310019714.2A CN201310019714A CN103936652A CN 103936652 A CN103936652 A CN 103936652A CN 201310019714 A CN201310019714 A CN 201310019714A CN 103936652 A CN103936652 A CN 103936652A
Authority
CN
China
Prior art keywords
compound
corticosterone
hydroxy
preparation
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201310019714.2A
Other languages
Chinese (zh)
Other versions
CN103936652B (en
Inventor
姚旻
袁哲东
杨玉雷
张浩宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CN201310019714.2A priority Critical patent/CN103936652B/en
Publication of CN103936652A publication Critical patent/CN103936652A/en
Application granted granted Critical
Publication of CN103936652B publication Critical patent/CN103936652B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the technical field of a method for preparation of an anti-HCV drug Boceprevir. The present invention provides compounds IV (F-1) of a formula as follows. The preparation of the compounds is simple and of high yield. The compounds can be used for synthesis of the anti-HCV drug Boceprevir. The present invention provides new implication and an approach for the synthesis of the anti-HCV drug Boceprevir. Furthermore, a UV chromophore of the compounds makes the compounds more convenient to detect than compounds prepared by a conventional synthesis method, and additionally introduction of a benzyl group to a hydroxyl group avoids side reactions caused by the nucleophilicity of the hydroxyl group during a condensation step. There are certain advantages compared to an existing synthesis method.

Description

Intermediate IV of anti-the third liver medicine Boceprevir and its preparation method and application
Technical field
The present invention relates to the preparation method's technical field for anti-the third liver medicine Boceprevir.
Background technology
In global range, the infection rate of hepatitis C virus (hepatitis C virus, HCV) is about 3%, and the total number of persons of infection is about 200,000,000.Because the high infection rate of HCV also can cause potential complication as serious in liver cirrhosis, liver cancer etc., thereby HCV is a serious threat of human life's health.According to Simmonds naming system, it is I-VI that HCV can be divided into 6 oligogene types, various several hypotypes (as Ia, Ib, IIa, IIb, IIIa, IIIb etc.) that can be divided into again.HCV the infected of China approximately 4,000 ten thousand, and wherein 69% is I type infection (taking Ib type as main).The method for the treatment of chronic hepatitis C is mainly polyoxyethylene glycol Interferon, rabbit (PEG-IFN α) and ribavirin (RBV) drug combination at present, this kind of therapy patient of approximately 50% in HCV I type patient can not produce lasting virological response, and there is untoward reaction, thereby need the effective medicine of exploitation badly.Due to this needs, anti-HCV new drug development is very active, has at present more than 50 planting anti-HCV drug candidate or grantedly carrying out clinical trial.In these medicines, Victrelis (boceprevir) is treated adult's chronic hepatitis C on May 13rd, 2011 by U.S. FDA approval and polyoxyethylene glycol Interferon, rabbit and ribavirin coupling.
Boceprevir(structure is as above) be the chronic hepatitis C curative by the exploitation of Schering Plough company of the U.S., it is a kind of orally active HCV NS3 proteinase inhibitor, that the high NS3 of a kind of tool is suppressed to amino-acid residue on active 11 peptides carries out systemic brachymemma and modification and the micromolecular inhibitor found, can catch the Serine of NS3 reactive site, on its keto-amide carbonyl carbon therewith Serine in conjunction with forming covalency adducts, thereby cause NS3 inactivation.A research that is published in " New England Journal of Medicine " shows, for untreated chronic hcv genotype I type infected patient of the past, on polyoxyethylene glycol Interferon, rabbit-ribavirin standard care basis, add with Boceprevir, compared with simple standard care, can significantly increase the virological response rate that continues.
The synthesis strategy of Boceprevir mainly contains two kinds, patent WO02/08244A2 and J.Med.Chem.2006, and 49,6074-6086 has reported that three fragments are once hydrolyzed last oxidation pendant hydroxyl group and obtain the synthesis strategy of Boceprevir through twice condensation.Specific as follows:
Patent WO2008/079216 has reported the initial oxidation pendant hydroxyl group synthesis strategy of the Boceprevir of condensation again, specific as follows:
The patent that other are relevant or document are all the optimize and improves (specifically can be referring to US2004/018914, US2006/043950, US2007/025804 etc.) that carry out on the basis of above two kinds of synthesis strategies.But all there is a same problem in existing synthetic method: owing to all not existing obvious chromophoric group event reaction detection and intermediate control comparatively to bother in the structure of each intermediate.In a tactful condensation step, there is exposed hydroxyl in addition, will inevitably cause side reaction occur, in the process of actually operating also just so.The present inventor replaces by introducing in a certain intermediate or unsubstituted benzyl has successfully solved the problem of detection difficult and condensation step side reaction, consider the importance of hepatitis C virus (" HCV ") proteinase inhibitor, the intermediate of novel this inhibitor of preparation is interesting all the time simultaneously.
Summary of the invention
Object of the present invention is exactly to solve the problem existing in above-mentioned existing synthetic Boceprevir method, and a kind of new midbody compound is provided, preparation Boceprevir or this compounds that can simple and effective.
For reaching above-mentioned purpose, the technical scheme that the present invention takes is as follows:
Following general formula compound F-1:
R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
Above-mentioned new general formula compound F-1, can be for the preparation of hepatitis C (HCV) the proteinase inhibitor Boceprevir with following structure
The compound of formula F-1 can make Boceprevir through following reaction path
A) in organic solvent, under acidic conditions, make compound F 17-hydroxy-corticosterone-1 deprotection base, obtain compound F 17-hydroxy-corticosterone-2
B), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone-2 and compound G-3 condensation obtain formula 1 compound
C) formula 1 compound can conveniently be prepared into formula 2 compounds through hydro-reduction, and formula 2 compound oxidations obtain ultimate aim compd B oceprevir
R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
The acid that step a) is used comprises hydrochloric acid, sulfuric acid, trifluoroacetic acid, preferably hydrochloric acid.With respect to compound F 17-hydroxy-corticosterone-1, sour that consumption can be 1 molar equivalent to 20 molar equivalent, preferably 1 molar equivalent to 10 molar equivalent, more preferably 1 molar equivalent to 5 molar equivalent uses.Available solvent comprises ether solvent, as ether, THF, methyl tertiary butyl ether, THP, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably dioxane.Reaction can, at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, be carried out at the temperature of more preferably 0 DEG C～25 DEG C approximately 1 hour or until react completely.
Step b) can with alkali comprise triethylamine, DIPEA, pyridine, N-methylmorpholine, preferably N-methylmorpholine and DIPEA.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of alkali can be at 2 molar equivalent to 8 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.Available condensing agent comprises 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), benzotriazole-1-base oxygen base three (dimethylamino) phosphorus hexafluorophosphate (BOP), phosphofluoric acid benzotriazole-1-base-oxygen base tripyrrole alkyl (PyBOP), N, N'-carbonyl dimidazoles (CDI), 2-(7-azo benzotriazole)-N, N, N', N'-tetramethyl-urea phosphofluoric acid ester (HATU), 2-(7-azo benzotriazole)-tetramethyl-urea phosphofluoric acid ester (HATU), >=99.5% (HPLC) (HBTU), N, N'-dicyclohexylcarbodiimide (DCC), preferably EDCI, BOP, PyBOP, HATU, more preferably EDCI and HATU.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of condensing agent can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.For promoting reaction to carry out, can also add additive, available additive comprises 1-hydroxyl-7-azo benzotriazole (HOAT), I-hydroxybenzotriazole (HOBT), >=99% (HPLC).With respect to compound F 17-hydroxy-corticosterone-1, the consumption of additive is at 0 to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of compound G-3 can be at 1 molar equivalent to 2 molar equivalent, preferably 1 molar equivalent to 1.5 molar equivalent, and more preferably 1 molar equivalent to 1.2 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Esters solvent, such as ethyl acetate etc., and other solvents, such as DMF, DMSO, acetonitrile etc. or its suitable mixture.Preferred solvent is other solvents, more preferably DMF and acetonitrile.
The method of formula 2 compound preparation formula 3 compd B oceprevir can be referring to patent US2006/043950, WO02/08244A2, J.Med.Chem.2006,49,6074-6086, US8188137B2.
The preparation method of above-mentioned general formula F-1 compound, is in organic solvent, under alkali and condensing agent existence condition, the compound F 17-hydroxy-corticosterone of following formula and compound G-2 condensation is obtained:
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
Available alkali comprises triethylamine, DIPEA, pyridine and N-methylmorpholine, preferably N-methylmorpholine and DIPEA.With respect to compound F 17-hydroxy-corticosterone, the consumption of alkali can be 2 molar equivalent to 8 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.Available condensing agent comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC, preferably EDCI, BOP, PyBOP and HATU, more preferably EDCI and HATU.With respect to compound F 17-hydroxy-corticosterone, condensing agent consumption can be 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.Step a) also can add additive, and additive comprises HOBT and HOAT etc.With respect to compound F 17-hydroxy-corticosterone, additive amount can be 0 to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably from about 1 molar equivalent to 2 molar equivalent uses.With respect to compound F 17-hydroxy-corticosterone, compound G-2 conventionally can approximately 1 molar equivalent to approximately 2 molar equivalents, preferably 1 molar equivalent to 1.5 molar equivalent, more preferably 1 molar equivalent to 1.2 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Esters solvent, such as ethyl acetate etc., and other solvents, such as DMF, DMSO, acetonitrile etc. or its suitable mixture.Preferred solvent is other solvents, more preferably DMF and acetonitrile.Reaction can, at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, be carried out at the temperature of more preferably 0 DEG C～25 DEG C approximately 24 hours or until react completely.
Compound F 17-hydroxy-corticosterone, can be by compd E in organic solvent, and under acidic conditions, deprotection base obtains:
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
Available acid comprises hydrochloric acid, sulfuric acid, trifluoroacetic acid, preferably hydrochloric acid.With respect to compd E, sour that consumption can be at 1 molar equivalent to 20 molar equivalent, preferably 1 molar equivalent to 10 molar equivalent, more preferably 1 molar equivalent to 5 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably dioxane.Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, more preferably at the temperature of 0～25 DEG C, carry out approximately 1 hour or until react completely.
Compd E, the Compound D of available following formula, in organic solvent, under alkali existence condition, directly with strong aqua is reacted is obtained after reacting with Vinyl chloroformate
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
The available alkali of above-mentioned reaction comprises triethylamine, DIPEA, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide, potassium hydroxide, preferably triethylamine, DIPEA and N-methylmorpholine, more preferably triethylamine.With respect to Compound D, the consumption of alkali is recommended as 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, the consumption of Vinyl chloroformate can be extremely approximately 5 molar equivalents of 1 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, strong aqua consumption can be 1 molar equivalent to 8 molar equivalent, preferably 1 molar equivalent to 5 molar equivalent, and more preferably 1 molar equivalent to 3 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, carry out approximately 2 hours or until react completely at the temperature of more preferably 0 DEG C～25 DEG C.
Compound D, can be in organic solvent, under alkali effect, Compound C hydrolysis is obtained:
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
Said hydrolyzed reaction, available alkali comprises potassium hydroxide, sodium hydroxide, lithium hydroxide, preferably sodium hydroxide and lithium hydroxide, more preferably lithium hydroxide.With respect to Compound C, the consumption of alkali can be 1 molar equivalent to 10 molar equivalent, preferably 1 molar equivalent to 5 molar equivalent, and more preferably 1 molar equivalent to 4 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc.; Protonic solvent, such as methyl alcohol, ethanol, water etc. or its suitable mixture.Preferred solvent is mixed solvent, more preferably tetrahydrofuran (THF)/methanol mixed solvent.This reaction can be at 0 DEG C～60 DEG C, preferably 0～40 DEG C, carry out approximately 4 hours or until react completely at the temperature of more preferably 10 DEG C～25 DEG C.
Compound C can, by the compd B of following formula, in organic solvent, under catalyst action, through hydrazine hydrate effect obtain after reacting with tert-Butyl dicarbonate again:
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
Available catalyzer can be DMAP, triethylamine, butyllithium, sodium hydroxide etc., preferably DMAP and triethylamine, more preferably DMAP.With respect to compd B, the consumption of catalyzer conventionally can be at 0.2 molar equivalent to 3 molar equivalent, preferably 0.2 molar equivalent to 1 molar equivalent, and more preferably 0.2 molar equivalent to 0.5 molar equivalent uses.With respect to compd B, the consumption of tert-Butyl dicarbonate conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.With respect to compd B, the consumption of hydrazine hydrate conventionally can be at 2 molar equivalent to 10 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.With tert-Butyl dicarbonate be used as the used time can solvent comprise ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).When hydrazinolysis can with solvent comprise ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Protonic solvent, such as methyl alcohol, ethanol, water etc. or its suitable mixture.Preferred solvent is mixed solvent, more preferably the mixed solvent of tetrahydrofuran (THF)/methyl alcohol.Compd B can be under 25 DEG C～reflux temperature with reacting of tert-Butyl dicarbonate, and preferably 50 DEG C～reflux temperature, more preferably carries out under reflux temperature, approximately 8 hours or until react completely; Hydrazinolysis reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～approximately 25 DEG C, carry out approximately 4 hours or until react completely at the temperature of more preferably 10 DEG C～25 DEG C.
Compd B can, by the compd A of following formula, in organic solvent, under alkali existence condition, react and obtain with replacement or unsubstituted benzyl halide:
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.
In above-mentioned replacement or unsubstituted benzyl halide, X can be chlorine or bromine, and preferably X is bromine; R can be hydrogen, C1-C6 alkyl or C1-C6 alkoxyl group, and preferably R is hydrogen or C1-C3 alkyl; R can be at phenyl ring the position of substitution not arbitrarily, and preferably R is in contraposition.With respect to compd A, the consumption of replacement or unsubstituted benzyl halide conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 1.3 molar equivalent uses.Available alkali comprises potassium tert.-butoxide, sodium hydride, potassium hydride KH, two (trimethyl silicon based) Lithamide, two (trimethyl silicon based) sodium amide, two (trimethyl silicon based) potassium amide, lithium diisopropylamine, butyllithium, preferably potassium tert.-butoxide, sodium hydride, two (trimethyl silicon based) Lithamide, more preferably sodium hydride.With respect to compd A, alkali conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 1.5 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).Reaction can be at-25 DEG C～25 DEG C, preferably-10 DEG C～10 DEG C, carry out approximately 2 hours or until react completely at the temperature of more preferably-5 DEG C～0 DEG C.
Compd A of the present invention can be prepared by means known in the art, in detail referring to Chinese patent application 201210200429.6.
The invention provides a kind of new compound F 17-hydroxy-corticosterone-1, the preparation of this compounds, operation is easy, and yield is higher.Use this compounds to can be used for the synthetic of anti-the third liver medicine Boceprevir, this is that anti-the third liver medicine Boceprevir synthetic provides new thinking and method.And convenient with the more original synthetic method detection of ultraviolet chromophoric group in such compound molecule, on hydroxyl, the side reaction causing because of hydroxyl nucleophilicity in condensation step has been avoided in the introducing of benzyl in addition, has certain advantage compared with existing synthetic method.
Embodiment
The reactions steps below relating to for the preferred embodiment of the present invention, outside indicating, chemical and solvent that the present invention is all obtain from commercial channel, use front without being further purified.
Embodiment 1-9:R is the preparation of formula 1 compound of hydrogen
Embodiment 1: the preparation of compd B
Compd A (5g, 20.6mmol) is dissolved in 40ml DMF and is added in there-necked flask, is cooled to-5 DEG C, add NaH (60% in batches, 1.1g, 26.8mmol), stir 1h, at-5 DEG C, drip 40ml BnBr (4.2g, DMF solution 24.7mmo), dropwise at this temperature and stir 2h, add frozen water cancellation reaction, extract with ethyl acetate, on a small quantity repeatedly, merge organic phase, desolventize and obtain yellow oil with anhydrous sodium sulfate drying after saturated common salt water washing steaming, it is white solid that column chromatography obtains 6.2g compd B, yield 90.4%, m/z (MH+) 334.16, 1H NMR (400MHz, CDCl3) δ 1.31 (t, 3H), 1.41-1.57 (m, 4H), 1.64-1.74 (m, 2H), 1.77 (s, 3H), 1.96-2.06 (m, 2H), 2.25-2.29 (m, 1H), 3.95 (d, 1H), 4.19-4.25 (m, 3H), 4.28 (d, 1H), 4.81 (d, 1H), 5.63 (d, 1H), 7.30-7.35 (m, 5H).
Embodiment 2: the preparation of Compound C
Compd B (5g, 15mmol), DMAP (0.37g, 3mmol) are dissolved in 60ml THF, add (Boc) 2o (6.88ml, 30mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 60ml methyl alcohol and hydrazine hydrate (3g, 60mmol) after stirring 4h, add the dilution of 200ml methylene dichloride, reaction solution is successively with 1N HCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 4.4g Compound C, yield 75.0%, m/z (MNa+) 414.06, 1H NMR (400MHz, CDCl3) δ 1.32 (t, 3H), 1.44 (s, 9H), 1.48-1.68 (m, 4H), 1.78-1.87 (m, 2H), 2.02-2.11 (m, 2H), 2.33-2.37 (m, 1H), 3.98 (m, 1H), 4.20-4.32 (m, 3H), 4.43 (d, 1H), 4.65 (d, 1H), 4.81 (d, 1H), 7.30-7.37 (m, 5H).
Embodiment 3: the preparation of Compound D
Compound C (2g, 5mmol) be dissolved in 20ml MeOH/THF (v/v1:1) solution, add 20ml1M LiOH solution, stirring at room temperature 4h, adds 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, and after anhydrous sodium sulfate drying steaming desolventize, obtaining Compound D is white solid 1.91g, yield 100%, m/z (MNa+) 386.13.
Embodiment 4: the preparation of compd E
Compound D (1.91g, 5mmol) be dissolved in the anhydrous THF of 30ml and be cooled to 0 DEG C, add triethylamine (1.9ml, 12.5mmol), add Vinyl chloroformate (1.2ml, 11mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (2ml, 13.5mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, it is a white solid that column chromatography obtains 3.30g compd E, yield 71.2%.m/z(MNa+)385.16,1H?NMR(400MHz,CDCl3)δ1.44(s,9H),1.61-1.70(m,4H),1.76-1.90(m,2H),2.03-2.10(m,2H),2.34-2.40(m,1H),3.80-3.98(m,1H),4.47(s,1H),4.60-4.67(m,2H),5.50(s,1H),6.46(s,1H),7.28-7.41(m,5H)。
Embodiment 5: the preparation of compound F 17-hydroxy-corticosterone
By compd E (422mg, 1.12mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 350mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 263.13.
Embodiment 6: the preparation of formula 1 compound
G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (117mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 177mg formula 1 compound, it is a white solid, yield 78.0%, m/z (MNa+) 634.34, 1H NMR (400MHz, DMSO-d) δ 0.89 (m, 9H), 0.82-1.00 (m, 6H), 1.17 (s, 9H), 1.26 (m, 1H), 1.43 (m, 1H), 1.65-1.74 (m, 4H), 1.78-1.94 (m, 2H), 2.01-2.08 (m, 2H), 2.36-2.40 (m, 1H), 3.74-3.76 (m, 2H), 3.92-3.97 (m, 1H), 4.11 (d, 1H), 4.26 (s, 1H), 4.47 (s, 1H), 4.60-4.67 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.28-7.46 (m, 5H), 7.76-8.04 (br, 2H), 8.20-8.30 (s, 1H).
Embodiment 7: the preparation of compound F 17-hydroxy-corticosterone-1
G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, adds NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) is added in 8ml DMF, this solution is added in the reaction soln of G-2, and 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 146mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 79.2%, m/z (MNa+) 522.30, 1HNMR (400MHz, DMSO-d) δ 0.92-1.03 (m, 6H), 1.23-1.26 (m, 1H), 1.44 (s, 9H), 1.46-1.50 (m, 1H), 1.64-1.74 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.38-2.44 (m, 1H), 3.54-3.72 (m, 2H), 3.91-3.97 (m, 1H), 4.13 (d, 1H), 4.49 (s, 1H), 4.60-4.69 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.25-7.49 (m, 5H).
Embodiment 8: compound F 17-hydroxy-corticosterone-2 synthetic
By compound F 17-hydroxy-corticosterone-1 (140mg, 0.28mmol) be dissolved in and in 3ml4NHCl/dioxane, stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 120mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 400.30.
Embodiment 9: the preparation of formula 1 compound
G-3 (78mg, 0.34mmol), HATU (128mg, 0.34mmol) are dissolved in 8mlDMF, and ice-water bath is cooling, add DIEA (0.18mml, 1.00mmol), stir 30min; In compound F 17-hydroxy-corticosterone-2 (120mg, 0.28mmol), be added in 8mlDMF, this solution be added in the reaction soln of G-2,0 DEG C of stirring is spent the night; In reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, and column chromatography obtains 118mg formula 1 compound, be a white solid, yield 68.7%.
Embodiment 10-18:R is methyl and the R preparation at formula 1 compound of contraposition
Embodiment 10: the preparation of compd B
Compd A (2g, 8.23mmol) be dissolved in 10mlDMF and be added in there-necked flask, be cooled to-5 DEG C, add NaH (60% in batches, 0.43g, 10.70mmol), stir 1h, at-5 DEG C, drip 10ml to methyl bromobenzyl (1.83g, DMF solution 9.88mmo), dropwise at this temperature and stir 2h, add frozen water cancellation reaction, extract with ethyl acetate, on a small quantity repeatedly, merge organic phase, with anhydrous sodium sulfate drying after saturated common salt water washing, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 2.4g compd B, yield 82.5%, 1HNMR (400MHz, CDCl3) δ 1.31 (t, 3H), 1.43-1.64 (m, 4H), 1.74-1.78 (m, 2H), 1.83 (s, 3H), 1.97-2.05 (m, 2H), 2.25-2.29 (m, 1H), 2.34 (s, 3H), 4.00 (d, 2H), 4.17-4.33 (m, 4H), 4.77 (d, 1H), 5.58 (d, 1H), 7.16 (d, 2H), 7.23 (d, 2H).
Embodiment 11: the preparation of Compound C
Compd B (1.8g, 5.19mmol), DMAP (0.13g, 1.04mmol) are dissolved in 20mlTHF, add (Boc) 2o (2.4ml, 10.38mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 20ml methyl alcohol and hydrazine hydrate (1.04g, 20.76mmol) after stirring 4h, add the dilution of 100ml methylene dichloride, reaction solution is successively with 1NHCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 1.34g Compound C, yield 63.7%, m/z (MNa+) 428.06, 1HNMR (400MHz, CDCl3) δ 1.32 (t, 3H), 1.43 (s, 9H), 1.50-1.67 (m, 4H), 1.76-1.91 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.33 (m, 1H), 2.35 (s, 3H), 3.94-3.98 (m, 1H), 4.00 (d, 1H), 4.17-4.38 (m, 3H), 4.64 (d, 1H), 4.79 (d, 1H), 7.17 (d, 2H), 7.27 (d, 2H).
Embodiment 12: the preparation of Compound D
Compound C (1.2g, 2.96mmol) is dissolved in 20mlMeOH/THF (v/v1:1) solution, adds 20ml1MLiOH solution, stirring at room temperature 4h, add 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, anhydrous sodium sulfate drying steams and removes, and obtains Compound D 1.2g after solvent, is white solid, yield 100%, m/z (MNa+) 400.13.
Embodiment 13: the preparation of compd E
Compound D (1.2g, 3.19mmol) be dissolved in the anhydrous THF of 20ml and be cooled to 0 DEG C, add triethylamine (1.1ml, 7.98mmol), add Vinyl chloroformate (0.7ml, 7.02mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (1ml, 8.61mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, column chromatography obtains 831mg compd E, it is a white solid, yield 69.3%, m/z (MNa+) 399.16, 1H NMR (400MHz, CDCl3) δ 1.43 (s, 9H), 1.60-1.71 (m, 4H), 1.77-1.93 (m, 2H), 2.00-2.10 (m, 2H), 2.35 (s, 3H), 2.36-2.40 (m, 1H), 3.83-3.98 (m, 1H), 4.50 (s, 1H), 4.62-4.69 (m, 2H), 5.50 (s, 1H), 6.47 (s, 1H), 7.18 (d, 2H), 7.25 (d, 2H).
Embodiment 14: the preparation of compound F 17-hydroxy-corticosterone
By compd E (400mg, 1.06mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 330mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 277.13.
Embodiment 15: the preparation of compound 1
G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.38mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 173mg formula 1 compound, it is a white solid, yield 72.7%, m/z (MNa+) 648.34, 1H NMR (400MHz, DMSO-d) δ 0.88-0.92 (m, 9H), 0.81-1.02 (m, 6H), 1.18 (s, 9H), 1.27 (m, 1H), 1.45 (m, 1H), 1.68-1.75 (m, 4H), 1.81-1.94 (m, 2H), 2.03-2.09 (m, 2H), 2.33-2.41 (m, 1H), 2.35 (s, 3H), 3.75-3.77 (m, 2H), 3.92-3.97 (m, 1H), 4.13 (d, 1H), 4.25 (s, 1H), 4.44 (s, 1H), 4.61-4.67 (m, 2H), 5.48 (s, 1H), 6.42 (s, 1H), 7.17 (d, 2H), 7.23 (d, 2H), 7.77-8.04 (br, 2H), 8.20-8.28 (s, 1H).
Embodiment 16: the preparation of compound F 17-hydroxy-corticosterone-1
G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.38mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-2, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 139mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 73.1%, m/z (MNa+) 536.30, 1H NMR (400MHz, DMSO-d) δ 0.90-1.03 (m, 6H), 1.22-1.26 (m, 1H), 1.44 (s, 9H), 1.48-1.51 (m, 1H), 1.62-1.71 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.34 (s, 3H), 2.37-2.44 (m, 1H), 3.54-3.70 (m, 2H), 3.90-3.97 (m, 1H), 4.13 (d, 1H), 4.52 (s, 1H), 4.60-4.69 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.18 (d, 2H), 7.23 (d, 2H).
Embodiment 17: compound F 17-hydroxy-corticosterone-2 synthetic
By compound F 17-hydroxy-corticosterone-1 (139mg, 0.27mmol) be dissolved in 3ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 120mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 414.30.
Embodiment 18: the preparation of formula 1 compound
G-3 (78mg, 0.34mmol), HATU (128mg, 0.34mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add DIEA (0.18mml, 1.00mmol), stir 30min, compound F 17-hydroxy-corticosterone-2 (120mg, 0.27mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-3, 0 DEG C of stirring is spent the night, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 102mg formula 1 compound, it is a white solid, yield 60.2%.
Embodiment 19-27:R is methoxyl group and the R preparation at formula 1 compound of contraposition
Embodiment 19: the preparation of compd B
Compd A (4g, 16.46mmol) is dissolved in 10mlDMF and is added in there-necked flask, is cooled to-5 DEG C; After adding NaH (60%, 0.86g, 21.40mmol), stir 1h in batches; At-5 DEG C, drip the DMF solution of 10ml to methoxyl group benzyl chloride (3.08g, 19.75mmol), dropwise at this temperature and stir 2h; Add frozen water cancellation reaction, with ethyl acetate extraction, on a small quantity repeatedly, merge organic phase, desolventize and obtain yellow oil with anhydrous sodium sulfate drying steaming after saturated common salt water washing; It is white solid that column chromatography obtains 2.3g compd B, yield 37.9%, m/z (MH+) 364.16
Embodiment 20: the preparation of Compound C
Compd B (2.0g, 5.51mmol), DMAP (134mg, 1.10mmol) are dissolved in 20mlTHF, add (Boc) 2o (2.5ml, 11.02mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 20ml methyl alcohol and hydrazine hydrate (1.10g, 22.04mmol) after stirring 4h, add the dilution of 100ml methylene dichloride, reaction solution is successively with 1N HCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 1.51g Compound C, yield 65.3%, (MNa+) 444.06.
Embodiment 21: the preparation of Compound D
Compound C (1g, 2.57mmol) be dissolved in 20mlMeOH/THF (v/v1:1) solution, add 20ml1MLiOH solution, stirring at room temperature 4h, adds 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, and it is white solid that anhydrous sodium sulfate drying obtains Compound D 950mg after steaming and desolventizing, yield 100%, m/z (MNa+) 416.13.
Embodiment 22: the preparation of compd E
Compound D (900mg, 2.29mmol) be dissolved in the anhydrous THF of 20ml and be cooled to 0 DEG C, add triethylamine (0.8ml, 5.73mmol), add Vinyl chloroformate (0.5ml, 5.04mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (0.7ml, 8.61mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, it is a white solid that column chromatography obtains 587mg compd E, yield 65.4%, m/z (MNa+) 415.16.
Embodiment 23: the preparation of compound F 17-hydroxy-corticosterone
By compd E (950mg, 2.42mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 795mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 293.13.
Embodiment 24: the preparation of compound 1
G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with dichloromethane extraction reaction solution, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 145mg formula 1 compound, it is a white solid, yield 61.3%, m/z (MNa+) 664.34, 1H NMR (400MHz, DMSO-d) δ 0.87-0.92 (m, 9H), 0.82-1.02 (m, 6H), 1.18 (s, 9H), 1.28 (m, 1H), 1.44 (m, 1H), 1.66-1.75 (m, 4H), 1.82-1.94 (m, 2H), 2.03-2.09 (m, 2H), 2.33-2.41 (m, 1H), 3.75-3.77 (m, 2H), 3.83 (s, 3H), 3.92-3.97 (m, 1H), 4.13 (d, 1H), 4.25 (s, 1H), 4.44 (s, 1H), 4.61-4.67 (m, 2H), 5.48 (s, 1H), 6.42 (s, 1H), 6.90 (d, 2H), 6.99 (d, 2H), 7.77-8.04 (br, 2H), 8.20-8.28 (s, 1H).
Embodiment 25: the preparation of compound F 17-hydroxy-corticosterone-1
G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-2, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 126mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 64.6%, m/z (MNa+) 552.30, 1H NMR (400MHz, DMSO-d) δ 0.91-1.03 (m, 6H), 1.20-1.26 (m, 1H), 1.44 (s, 9H), 1.48-1.51 (m, 1H), 1.62-1.71 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.38-2.44 (m, 1H), 3.54-3.70 (m, 2H), 3.84 (s, 3H), 3.91-3.97 (m, 1H), 4.11 (d, 1H), 4.52 (s, 1H), 4.63-4.70 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 6.91 (d, 2H), 7.02 (d, 2H).
Embodiment 26: compound F 17-hydroxy-corticosterone-2 synthetic
By compound F 17-hydroxy-corticosterone-1 (120mg, 0.23mmol) be dissolved in and in 3ml4NHCl/dioxane, stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 105mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 430.30.
Embodiment 27: the preparation of formula 1 compound
G-3 (30mg, 0.13mmol), HATU (50mg, 0.13mmol) be dissolved in 8mlDMF, ice-water bath is cooling, add DIEA (0.1ml, 0.57mmol), stir 30min, compound F 17-hydroxy-corticosterone-2 (50mg, 0.11mmol) be added in 8mlDMF, this solution is added in the reaction soln of G-2, 0 DEG C of stirring is spent the night, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 40mg formula 1 compound, it is a white solid, yield 57.2%
Embodiment 28: formula 1 compound preparation formula 2 compounds taking R as hydrogen
By formula 1 compound (50mg, 0.08mmol) be dissolved in 20ml methyl alcohol, add the palladium carbon of 10mg10%, be placed on 40 DEG C, in the hydrogen atmosphere of 0.7MP, stir and spend the night, with diatomite filtering palladium carbon, after gained filtrate is concentrated, obtaining formula (2) compound 39mg, is a white solid, yield 92.3%, m/z (MNa+) 544.42, HPLC shows that purity is 91.2%.
Embodiment 5
Embodiment 29: taking R as methyl and R at formula 1 compound preparation formula 2 compounds of contraposition
By formula 1 compound (50mg, 0.08mmol) be dissolved in 20ml methyl alcohol, add the palladium carbon of 10mg10%, be placed on 40 DEG C, in the hydrogen atmosphere of 0.7MP, stir and spend the night, after concentrating with diatomite filtering palladium carbon gained filtrate, obtain formula (2) compound 37mg, it is a white solid, yield 89.5%, m/z (MNa+) 544.42, HPLC shows that purity is 90.3%.

Claims (25)

1. following general formula compound F-1:
R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group.
2. general formula compound F-1 as claimed in claim 1, is characterized in that: R is in contraposition.
3. general formula compound F-1 as claimed in claim 1 or 2, is characterized in that: R is the alkyl of hydrogen or C1-C3.
4. general formula compound F-1 as claimed in claim 3, is characterized in that: R is hydrogen.
5. the application of any described compound F 17-hydroxy-corticosterone-1 of claim 1-4, is characterized in that: for the preparation of the compound 2 of following formula
6. the application of compound F 17-hydroxy-corticosterone-1 as claimed in claim 5, is characterized in that: compound 2 preparation processes are as follows:
A) in organic solvent, under acidic conditions, make compound F 17-hydroxy-corticosterone-1 deprotection base, obtain compound F 17-hydroxy-corticosterone-2
B), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone-2 and compound G-3 condensation obtain formula 1 compound
C) formula 1 compound obtains formula 2 compounds through hydro-reduction
R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.
7. the application of compound F 17-hydroxy-corticosterone-1 as claimed in claim 6, is characterized in that: the acid that step a) is used comprises hydrochloric acid, sulfuric acid and trifluoroacetic acid.
8. the application of compound F 17-hydroxy-corticosterone-1 as claimed in claim 6, is characterized in that: the alkali that step b) is used comprises triethylamine, DIPEA, pyridine and N-methylmorpholine.
9. the application of compound F 17-hydroxy-corticosterone-1 as claimed in claim 6, is characterized in that: the condensing agent that step b) is used comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC.
10. the application of compound F 17-hydroxy-corticosterone-1 as claimed in claim 6, is characterized in that: step b) adds additive HOBT or HOAT.
The preparation method of 11. any described compound F 17-hydroxy-corticosterone-1 of claim 1-4, the method is in organic solvent, under alkali and condensing agent existence condition, following formula: compound F and compound G-2 condensation is obtained
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.
The preparation method of compound F 17-hydroxy-corticosterone-1 described in 12. claims 11, is characterized in that: the alkali of use comprises triethylamine, DIPEA, pyridine and N-methylmorpholine.
The preparation method of compound F 17-hydroxy-corticosterone-1 described in 13. claims 11, is characterized in that: the condensing agent of use comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC.
The preparation method of compound F 17-hydroxy-corticosterone-1 described in 14. claims 11, is characterized in that: add additive HOBT or HOAT.
15. as the preparation method of compound F 17-hydroxy-corticosterone-1 of claim 11-14 as described in arbitrarily, it is characterized in that: compound F 17-hydroxy-corticosterone is by compd E in organic solvent, and under acidic conditions, deprotection base obtains
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.
The preparation method of 16. compound F 17-hydroxy-corticosterone-1 as claimed in claim 15, is characterized in that: said acid comprises hydrochloric acid, sulfuric acid and trifluoroacetic acid.
The preparation method of 17. compound F 17-hydroxy-corticosterone-1 as claimed in claim 15, is characterized in that: compd E be Compound D in organic solvent, under alkali existence condition, directly react and obtain with strong aqua after reacting with Vinyl chloroformate
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.
The preparation method of 18. compound F 17-hydroxy-corticosterone-1 as claimed in claim 17, is characterized in that: said alkali comprises triethylamine, DIPEA, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide and potassium hydroxide.
The preparation method of 19. compound F 17-hydroxy-corticosterone-1 as claimed in claim 17, is characterized in that: said strong aqua mass concentration is 28-35%.
The preparation method of 20. compound F 17-hydroxy-corticosterone-1 as claimed in claim 17, is characterized in that: Compound D is in organic solvent, under alkali effect, Compound C hydrolysis is obtained
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.
The preparation method of 21. compound F 17-hydroxy-corticosterone-1 as claimed in claim 20, is characterized in that: said alkali comprises potassium hydroxide, sodium hydroxide and lithium hydroxide.
The preparation method of 22. compound F 17-hydroxy-corticosterone-1 as claimed in claim 20, is characterized in that: Compound C, by the compd B of following formula, in organic solvent, under catalyst action, through hydrazine hydrate effect obtains after reacting with tert-Butyl dicarbonate again
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.
The preparation method of 23. compound F 17-hydroxy-corticosterone-1 as claimed in claim 22, is characterized in that: said catalyzer is DMAP, triethylamine, butyllithium or sodium hydroxide.
The preparation method of 24. compound F 17-hydroxy-corticosterone-1 as claimed in claim 22, is characterized in that: compd B, by the compd A of following formula, in organic solvent, under alkali existence condition, reacts and obtains with replacement or unsubstituted benzyl halide
Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and X is chlorine or bromine.
The preparation method of 25. compound F 17-hydroxy-corticosterone-1 as claimed in claim 24, is characterized in that: said alkali comprises potassium tert.-butoxide, sodium hydride, potassium hydride KH, two (trimethyl silicon based) Lithamide, two (trimethyl silicon based) sodium amide, two (trimethyl silicon based) potassium amide, lithium diisopropylamine and butyllithium.
CN201310019714.2A 2013-01-18 2013-01-18 Intermediate compound IV of anti-hepatitis C medicine Boceprevir and its preparation method and application Expired - Fee Related CN103936652B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310019714.2A CN103936652B (en) 2013-01-18 2013-01-18 Intermediate compound IV of anti-hepatitis C medicine Boceprevir and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310019714.2A CN103936652B (en) 2013-01-18 2013-01-18 Intermediate compound IV of anti-hepatitis C medicine Boceprevir and its preparation method and application

Publications (2)

Publication Number Publication Date
CN103936652A true CN103936652A (en) 2014-07-23
CN103936652B CN103936652B (en) 2016-07-06

Family

ID=51184569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310019714.2A Expired - Fee Related CN103936652B (en) 2013-01-18 2013-01-18 Intermediate compound IV of anti-hepatitis C medicine Boceprevir and its preparation method and application

Country Status (1)

Country Link
CN (1) CN103936652B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079216A1 (en) * 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CN102206247A (en) * 2000-07-21 2011-10-05 先灵公司 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206247A (en) * 2000-07-21 2011-10-05 先灵公司 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2008079216A1 (en) * 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIKANTH VENKATRAMAN，等: "A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection", 《J. MED. CHEM.》 *

Also Published As

Publication number Publication date
CN103936652B (en) 2016-07-06

Similar Documents

Publication Publication Date Title
CA2615921C (en) Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
CN100480234C (en) N-(N-benzoyl-phenylalanyl)-phenylalanine dipeptide derivative, and preparing method and use thereof
CN107033087B (en) 1H-indazole-4-amine compounds and use thereof as IDO inhibitors
CA2654884A1 (en) Macrocyclic compounds as antiviral agents
KR20160099090A (en) Nucleotides for the treatment of liver cancer
CA2944256A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
US11702452B2 (en) Process for making arylomycin ring analogs
CN1172486A (en) Proline derivatives useful as inhibitors of human leukocyte elastase
ES2912881T3 (en) Procedure for preparing alpha-carboxamide pyrrolidine derivatives
WO2014093723A2 (en) Group-assistant-purification (gap) synthesis of velcade, dimeric analogs, and amino compounds
CN114478690A (en) Preparation method of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane derivative
CN103936651A (en) Intermediate III of anti-hepatitis C virus drug Boceprevir, and preparation method and application thereof
CN103936818A (en) Midbody I for anti-hepatitis C medicine Boceprevir as well as preparing method and application thereof
WO2009074020A1 (en) Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof
CN103936652A (en) Anti-HCV drug Boceprevir intermediate IV, preparation method and application thereof
CN103936616A (en) Anti-HCV drug Boceprevir intermediate II preparation method and application thereof
CN103936627B (en) Intermediate VII of anti-hepatitis medicine Boceprevir and its preparation method and application
WO2018113277A1 (en) Method for preparing ledipasvir and intermediate for preparing ledipasvir
CN103936628A (en) Intermediate V for anti-hepatitis C medicine Boceprevir as well as preparing method and application thereof
CN103936613A (en) Midbody VIII for anti-hepatitis C medicine Boceprevir as well as preparing method and application thereof
CN103936626A (en) Intermediate VI for anti-hepatitis C medicine Boceprevir as well as preparing method and application thereof
CN103936626B (en) Intermediate VI of anti-hepatitis C medicine Boceprevir and its preparation method and application
CN103936628B (en) Intermediate V of anti-hepatitis C medicine Boceprevir and its preparation method and application
CN110981879B (en) Method for preparing NS5A inhibitor-wipatasvir
ES2704056T3 (en) Epoxyketone compounds for the inhibition of enzymes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160411

Address after: 200040 Beijing West Road, Shanghai, No. 1320, No.

Applicant after: Shanghai Institute of pharmaceutical industry

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: 200040 Beijing West Road, Shanghai, No. 1320, No.

Applicant before: Shanghai Institute of pharmaceutical industry

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160706

Termination date: 20180118